A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China. Issue 4 (27th July 2017)

• Record Type: Journal Article
• Authors: Wu, Yueming; Feng, Jiang; Hu, Weiwei; Luo, Qingquan
• Is Part Of: Bioscience reports. Volume 37:Issue 4(2017)
• Publication Date: 2017-07-27
• Subjects: NSCLC -- nab-paclitaxel -- OS -- PFS -- second-line; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20170020
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract : We performed a randomized and placebo-controlled clinical study to investigate whether nab -paclitaxel can improve survival in patients with advanced non-small cell lung cancer (NSCLC) after unsuccessful first-line chemotherapy. Patients with stages III to IV advanced NSCLC after first-line platinum-based chemotherapy failure were randomly assigned in a 1:1 ratio to receive second-line treatment of nab -paclitaxel or placebo. Ninety two eligible patients were enrolled in the study. The median progression-free survival (PFS) was 4.6 months (95% confidence interval (CI): 3.4–6.7 months) for nab -paclitaxel, compared with 2.0 months (95% CI: 0.9–4.3 months) for placebo, representing a 56% reduction in disease progression (hazard ratio: 0.62; 95% CI: 0.33–0.81; P <0.001). The median overall survival (OS) was 6.3 months (95% CI: 3.9–8.2 months) for nab -paclitaxel, compared with 4.9 months (95% CI: 2.1–5.9 months) for placebo, representing a 22% reduction in disease progression (hazard ratio: 0.71; 95% CI: 0.33–0.85; P <0.001). Adverse events (AEs) were also observed for nab -paclitaxel. Nab -paclitaxel can improve survival in patients with advanced NSCLC after unsuccessful first-line chemotherapy.